Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2020

View Archived Issues

TXNIP inhibition nixes T2D

Supportive preclinical reported for PTX-COVID19-B vaccine candidate

First-in-human data presented for NTRX-07

Daiichi Sankyo patents new SIRT6 activators

Merck & Co. synthesizes HDAC inhibitors

Chinese researchers identify LPAR1 antagonists

Innate Tumor Immunity discloses NLRP3 agonists

New adenosine A2A receptor antagonists discovered by Nuvation Bio

Boehringer Ingelheim initiates first-in-human study of BI-764532

Structure-guided analysis unveils the mechanism of action of a dengue virus 2-specific inhibitor

SASS6 is involved in the proliferation of esophageal cancer and may be a novel therapeutic target

AstraZeneca is enrolling participants in phase I study of MEDI-8367

First patient enrolled in phase IIb/III study of ifenprodil for treatment of COVID-19

Six-month follow-up data announced from phase I study of INXN-4001

Anti-podocalyxin [225Ac]PODO-447 shows promise as immunotherapeutic for treating solid tumors

Dicerna provides data updates from clinical and preclinical developments

Topline data presented from phase III CARE-PWS study of LV-101

Phase II/III study of opaganib in patients with COVID-19 receives approval in Mexico

FDA clears IND for phase II study of TNX-102 SL

First patient dosed in a phase Ib/II study FGF-401 plus pembrolizumab

Study links mitochondrial DNA to abscopal response

Roche gives update on phase III IMpassion131 study of Tecentriq

GlycoNex initiates phase I study of GNX-102

First-in-human study of DC immunotherapy in patients with pancreatic adenocarcinoma

EC approves Xolair as treatment of severe chronic rhinosinusitis with nasal polyps

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...